Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

T-cell stimulant

DRUG CLASS:

T-cell stimulant

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	BRG01 Sensitive: B - Late Trials BRG01 Sensitive : B	BRG01 Sensitive: B - Late Trials BRG01 Sensitive : B
MSLN positive	Mesothelioma	MSLN positive	Mesothelioma	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN expression	Lung Cancer	MSLN expression	Lung Cancer	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN expression	Ovarian Cancer	MSLN expression	Ovarian Cancer	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN expression	Mesothelioma	MSLN expression	Mesothelioma	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN overexpression	Ovarian Cancer	MSLN overexpression	Ovarian Cancer	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3
MSLN overexpression	Malignant Pleural Mesothelioma	MSLN overexpression	Malignant Pleural Mesothelioma	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3
MSLN overexpression + TP53 mutation	Ovarian Cancer	MSLN overexpression + TP53 mutation	Ovarian Cancer	TC-210 Sensitive: C4 – Case Studies TC-210 Sensitive : C4	TC-210 Sensitive: C4 – Case Studies TC-210 Sensitive : C4
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	SAR443216 Sensitive: D – Preclinical SAR443216 Sensitive : D	SAR443216 Sensitive: D – Preclinical SAR443216 Sensitive : D
PD-L1 overexpression	Melanoma	PD-L1 overexpression	Melanoma	nivolumab + CDX 1127 Sensitive: D – Preclinical nivolumab + CDX 1127 Sensitive : D	nivolumab + CDX 1127 Sensitive: D – Preclinical nivolumab + CDX 1127 Sensitive : D